

tixagevimabum #

tixagevimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, receptor binding domain (RBD)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-453) [VH (*Homo sapiens*IGHV1-58*01 (98.0%) -(IGHD) -IGHJ3*02 (93.8%)) CDR-IMGT [8.8.16] (26-33.51-58.97-112) (1-123) -*Homo sapiens*IGHG1*03 G1m3, nG1m1, G1v21 CH2 Y15.1, T16, E18, G1v39 CH2 F1.3, E1.2, S116 (CH1 R120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>F (240), L1.2>E (241), M15.1>Y (258), S16>T (260), T18>E (262), P116>S (337) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-216')-disulfide with kappa light chain *Homo sapiens* (1'-216') [V-KAPPA (*Homo sapiens*IGKV3-20*01 (98.9%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.10] (27-33.51-53.90-99) (1'-109') -*Homo sapiens*IGKC*01 (100%) Km3 A45.1 (155), V101 (193) (110'-216')]; dimer (232-232":235-235")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
antiviral

tixagévimab

immunoglobuline G1-kappa anti-[*Homo sapiens* protéine spike (S) du coronavirus 2 du syndrome respiratoire aigu sévère (SARS-CoV-2), domaine de liaison au récepteur (RBD)], anticorps monoclonal *Homo sapiens*;
chaîne lourde gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens*IGHV1-58*01 (98.0%) -(IGHD) -IGHJ3*02 (93.8%)) CDR-IMGT [8.8.16] (26-33.51-58.97-112) (1-123) -*Homo sapiens*IGHG1*03 G1m3, nG1m1, G1v21 CH2 Y15.1, T16, E18, G1v39 CH2 F1.3, E1.2, S116 (CH1 R120 (220) (124-221), charnière 1-15 (222-236), CH2 L1.3>F (240), L1.2>E (241), M15.1>Y (258), S16>T (260), T18>E (262), P116>S (337) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-216')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-216') [V-KAPPA (*Homo sapiens*IGKV3-20*01 (98.9%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.10] (27-33.51-53.90-99) (1'-109') -*Homo sapiens*IGKC*01 (100%) Km3 A45.1 (155), V101 (193) (110'-216')]; dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
antiviral

tixagevimab

immunoglobulina G1-kappa anti-[*Homo sapiens* proteína espícula (S) del coronavirus 2 del síndrome respiratorio agudo severo (SRAS-CoV-2), dominio de unión al receptor (RBD)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens*IGHV1-58*01 (98.0%) -(IGHD) -IGHJ3*02 (93.8%)) CDR-IMGT [8.8.16] (26-33.51-58.97-112) (1-123) -*Homo sapiens*IGHG1*03 G1m3, nG1m1, G1v21 CH2 Y15.1, T16, E18, G1v39 CH2 F1.3, E1.2, S116 (CH1 R120 (220) (124-221), bisagra 1-15 (222-236), CH2 L1.3>F (240), L1.2>E (241), M15.1>Y (258), S16>T (260), T18>E (262), P116>S (337) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-216')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-216') [V-KAPPA (*Homo sapiens*IGKV3-20*01 (98.9%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.10] (27-33.51-53.90-99) (1'-109') -*Homo sapiens*IGKC*01 (100%) Km3 A45.1 (155), V101 (193) (110'-216')]; dímero (232-232":235-235")-bisdisulfuro, producido en las células ováricas de hámster chino (CHO), forma glicosilada alfa
antiviral

2420564-02-7

Heavy chain / Chaîne lourde / Cadena pesada
 QMQLVQSGPE VKKPGTSVKV SCKASGTFM SSAVQWVRQA RGQRLEWIGW 50
 IVIGSGNTNY AQKFQERVTI TRDMSTSTAY MELSSLRSED TAVYYCAAPY 100
 CSSISCNDFG DIWGGQTMVT VSSASTKGPS VFPLPAPSSK TSGGTAAALGC 150
 LVKDYFFPEFV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
 TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEF EGGPSVFLFP 250
 PKPKDLYIT REPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
 QYNSTYRVVS VLTVLHQDWL NGEKYKCKVS NKALPASIEK TISKAKQPR 350
 EPQVYTLPPS REEMTKQVVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
 PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSMVHEALHN HYTEKSLSL 450
 PGK 453

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSVLAWYQQK PGQAPRLLIY 50
 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ HYGSSRGWTF 100
 GQGTKVEIKR TVAAPSVEIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150
 KVDNALQSGN SQESVTEQDS KDSITYLSST LTLSKADYEK HKVYACEVTH 200
 QGLSSPVTKS FNRGEC 216

Post-translational modifications
 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22°-96' 101°-106' 150°-206' 267°-327' 373°-431'
 22°-96' 101°-106' 150°-206' 267°-327' 373°-431"
 Intra- H (CDR3) 101°-106'
 101°-106"
 Intra-L (C23-C104) 23°-89' 136°-196'
 23°-89" 136°-196"
 Inter-H-L (h 5-CL 126) 226°-216' 226°-216"
 Inter-H-H (h 11, h 14) 232°-232' 235°-235"

N-terminal glutamine cyclization to pyroglutamyl (pE, 5-oxoprolyl)
 H VH Q1:
 I, I"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 303, 303"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados.

C-terminal lysine clipping / Coupure de la lysine C-terminale / Recorte de lisina C-terminal
 H CHS K2:
 453, 453"

tozinameranum #
tozinameran

messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K986P and V987P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2, GenBank: MN908947.3) spike (S) glycoprotein, flanked by 5' and 3' untranslated regions and a 3' poly(A) tail; contains N1-methylpseudouridine instead of uridine (*all-U>m¹Ψ*).
immunological agent for active immunization (anti-SARS-CoV-2)

tozinaméran

ARN messenger (ARNm), protégé en 5', codant pour un variant de pré-fusion stabilisé en conformation (K986P et V987P) de la glycoprotéine spike (S) du SARS-CoV-2 (coronavirus 2 du syndrome respiratoire aigu sévère, GenBank: MN908947.3) complet, avec des codons optimisés, flanqués de régions 5' et 3' non traduites et d'une queue poly(A) 3'; contient de la N1-méthylpseudouridine au lieu de l'uridine (*tout-U>m¹Ψ*).
agent immunologique d'immunisation active (anti-SARS-CoV-2)

tozinamerán

RNA mensajero (mRNA), protegido en 5', que codifica para una variante pre-fusión de conformación estabilizada (K986P and V987P) de la glicoproteína de la espícula (S) del SRAS-CoV-2 (coronavirus 2 del síndrome respiratorio agudo severo, GenBank: MN908947.3) completa, con codones optimizados, flanqueada por regiones 5' y 3' no traducidas y una cola poly(A) en 3'; contiene N1-metilpseudouridina en lugar de uridina (*all-U>m¹Ψ*).
agente inmunológico para inmunización activa (anti-SRAS-CoV-2)

2417899-77-3

zansecimabum #

zansecimab

immunoglobulin G4-kappa, anti-[*Homo sapiens* ANGPT2 (angiopoietin 2)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-447) [VH (*Homo sapiens* IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10,G4v4 CH2 A1.3, A1.2 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 F1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS K>del (447)) (122-447)], (135-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (227-227":230-230")-bisdisulfide, produced in a Chinese hamster ovary (CHO) cell line derived from CHO-GSKO, glycoform alfa
angiogenesis inhibitor, immunomodulator

zansécimab

immunoglobuline G4-kappa anti-[*Homo sapiens* ANGPT2 (angiopoietin 2)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-447) [VH (*Homo sapiens* IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG4*01 G4v5 h P10,G4v4 CH2 A1.3, A1.2 (CH1 (122-219), charnière 1-12 S10>P (229) (220-231), CH2 F1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS K>del (447)) (122-447)], (135-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) dérivant de la lignée cellulaire CHO-GSKO, glycoforme alfa
inhibiteur de l'angiogénèse, immunomodulateur

zansecimab

inmunoglobulina G4-kappa anti-[*Homo sapiens* ANGPT2 (angiopoyetina 2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-447) [VH (*Homo sapiens* IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG4*01 G4v5 h P10,G4v4 CH2 A1.3, A1.2 (CH1 (122-219), bisagra 1-12 S10>P (229) (220-231), CH2 F1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS K>del (447)) (122-447)], (135-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (227-227":230-230")-bisdisulfuro, producido en las células ováricas de hámster chino (CHO) línea celular derivada de CHO-GSKO, forma glicosilada alfa
inhibidor de la angiogénesis, inmunomodulador